2.50
Hdl Handle:
http://hdl.handle.net/10541/72673
Title:
Alpha-v integrins as therapeutic targets in oncology.
Authors:
Nemeth, Jeffrey A; Nakada, Marian T; Trikha, M; Lang, Zhihui; Gordon, Michael S; Jayson, Gordon C ( 0000-0002-8515-8944 ) ; Corringham, Robert E; Prabhakar, Uma; Davis, Hugh M; Beckman, Robert A
Abstract:
Integrins are heterodimeric cell adhesion receptors that mediate intercellular communication through cell-extracellular matrix interactions and cell-cell interactions. Integrins have been demonstrated to play a direct role in cancer progression, specifically in tumor cell survival, tumor angiogenesis, and metastasis. Therefore, agents targeted against integrin function have potential as effective anticancer therapies. Numerous anti-integrin agents, including monoclonal antibodies and small-molecule inhibitors, are in clinical development for the treatment of solid and hematologic tumors. This review focuses on the role of alpha(v) integrins in cancer progression, the current status of integrin-targeted agents in development, and strategies for the clinical development of anti-integrin therapies.
Affiliation:
Centocor, Inc., Radnor, Pennsylvania 19087, USA. jnemeth@cntus.jnj.com
Citation:
Alpha-v integrins as therapeutic targets in oncology. 2007, 25 (7):632-46 Cancer Invest.
Journal:
Cancer Investigation
Issue Date:
Oct-2007
URI:
http://hdl.handle.net/10541/72673
DOI:
10.1080/07357900701522638
PubMed ID:
18027153
Type:
Article
Language:
en
ISSN:
1532-4192
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorNemeth, Jeffrey A-
dc.contributor.authorNakada, Marian T-
dc.contributor.authorTrikha, M-
dc.contributor.authorLang, Zhihui-
dc.contributor.authorGordon, Michael S-
dc.contributor.authorJayson, Gordon C-
dc.contributor.authorCorringham, Robert E-
dc.contributor.authorPrabhakar, Uma-
dc.contributor.authorDavis, Hugh M-
dc.contributor.authorBeckman, Robert A-
dc.date.accessioned2009-07-07T09:30:10Z-
dc.date.available2009-07-07T09:30:10Z-
dc.date.issued2007-10-
dc.identifier.citationAlpha-v integrins as therapeutic targets in oncology. 2007, 25 (7):632-46 Cancer Invest.en
dc.identifier.issn1532-4192-
dc.identifier.pmid18027153-
dc.identifier.doi10.1080/07357900701522638-
dc.identifier.urihttp://hdl.handle.net/10541/72673-
dc.description.abstractIntegrins are heterodimeric cell adhesion receptors that mediate intercellular communication through cell-extracellular matrix interactions and cell-cell interactions. Integrins have been demonstrated to play a direct role in cancer progression, specifically in tumor cell survival, tumor angiogenesis, and metastasis. Therefore, agents targeted against integrin function have potential as effective anticancer therapies. Numerous anti-integrin agents, including monoclonal antibodies and small-molecule inhibitors, are in clinical development for the treatment of solid and hematologic tumors. This review focuses on the role of alpha(v) integrins in cancer progression, the current status of integrin-targeted agents in development, and strategies for the clinical development of anti-integrin therapies.en
dc.language.isoenen
dc.subjectCancer Metastasisen
dc.subjectCancer Etiologyen
dc.subjectCancer Drug Therapyen
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Remodeling-
dc.subject.meshClinical Trials, Phase II as Topic-
dc.subject.meshHumans-
dc.subject.meshIntegrin alphaV-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshNeoplasms-
dc.subject.meshSignal Transduction-
dc.titleAlpha-v integrins as therapeutic targets in oncology.en
dc.typeArticleen
dc.contributor.departmentCentocor, Inc., Radnor, Pennsylvania 19087, USA. jnemeth@cntus.jnj.comen
dc.identifier.journalCancer Investigationen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.